Floatz logo

NEOMYCIN

Inflammatory Bowel Diseases

Thomas Jefferson UniversitymixtureEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Inflammatory Bowel Diseases cohort.

Asset / SponsorPhaseRating
MACROGOLS
Region Skane
Phase 4A
Prucalopride
Region Skane
Phase 4BBB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Cedars-Sinai Medical Center
Phase 4BBB
Epinephrine
Cedars-Sinai Medical Center
Phase 4BB
DEXAMETHASONE
Cedars-Sinai Medical Center
Phase 4BB

View all 31 →

Same molecule, other indications

NEOMYCIN is also rated in:

Surgical Site InfectionDormant
BBB
Indicative ·
72 / 100
View asset →
Rectum NeoplasmDormant
BB
Indicative ·
65 / 100
View asset →
Surgery--ComplicationsDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →